v3.26.1
SEGMENT REPORTING - Revenue (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
USD ($)
segment
brand
productFamily
Mar. 31, 2025
USD ($)
Segment reporting    
Number of operating segments | segment 2  
Number of reporting units | segment 2  
Established brand products | brand 20  
Product families | productFamily 130  
Net Revenues $ 237,462 $ 197,122
Cost of sales (excluding depreciation and amortization) 93,582 73,037
Research and Development expense 10,600 10,564
Selling, general, and administrative expense 73,655 76,528
Depreciation and amortization 20,919 22,891
Contingent consideration fair value adjustment (182) (12,092)
Operating income 38,888 26,194
Unrealized gain (loss) on investment in equity securities 5,753 (921)
Interest expense, net (3,769) (5,484)
Other (expense)income , net (651) 198
Income Before Income Tax Expense 40,221 19,987
Corporate and Unallocated    
Segment reporting    
Net Revenues 0 0
Cost of sales (excluding depreciation and amortization) 0 0
Research and Development expense 0 0
Selling, general, and administrative expense 16,945 32,684
Depreciation and amortization 20,919 22,891
Contingent consideration fair value adjustment (182) (12,092)
Operating income (37,682) (43,483)
Unrealized gain (loss) on investment in equity securities 5,753 (921)
Interest expense, net (3,769) (5,484)
Other (expense)income , net (651) 198
Income Before Income Tax Expense (36,349) (49,690)
Generics and Other | Operating Segments    
Segment reporting    
Net Revenues 109,220 103,040
Cost of sales (excluding depreciation and amortization) 59,592 46,501
Research and Development expense 7,789 6,588
Selling, general, and administrative expense 1,522 1,408
Depreciation and amortization 0 0
Contingent consideration fair value adjustment 0 0
Operating income 40,317 48,543
Unrealized gain (loss) on investment in equity securities 0 0
Interest expense, net 0 0
Other (expense)income , net 0 0
Income Before Income Tax Expense 40,317 48,543
Rare Disease and Brands | Operating Segments    
Segment reporting    
Net Revenues 128,242 94,082
Cost of sales (excluding depreciation and amortization) 33,990 26,536
Research and Development expense 2,811 3,976
Selling, general, and administrative expense 55,188 42,436
Depreciation and amortization 0 0
Contingent consideration fair value adjustment 0 0
Operating income 36,253 21,134
Unrealized gain (loss) on investment in equity securities 0 0
Interest expense, net 0 0
Other (expense)income , net 0 0
Income Before Income Tax Expense $ 36,253 $ 21,134